FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean‐Baptiste Bachet, Pascal Hammel et al.|New England Journal of Medicine|2018Cited by 2.8k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III TrialMarc Ychou, P. Rougier, Valérie Boige et al.|Journal of Clinical Oncology|2011Cited by 2.1k
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Jean François Seitz, Florence Castan et al.|JAMA Oncology|2022Cited by 322
Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate dataUlrich Ronellenfitsch, Katrin Jensen, Susan G. Urba et al.|European Journal of Cancer|2013Cited by 169
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN StudyEric Van Cutsem, Alberto Zaniboni, Erika Martinelli et al.|The Oncologist|2018Cited by 143